LAUSR

ease outcome, the prognosis of NKTCL is generally poor, and no targeted therapy is currently available. Recent studies indicated that L‐ASP‐based regimen, such as SMILE, AspMetDex and P‐GEMOX regimen were efficient in treating NKTCL. Using UPLC‐QTOFMS, we identified distinct metabolomic profile in NKTCL and suggested that metabolism‐targeted agents were key components. On the other hand, novel targeted agents, such as read‐through therapy to DDX3X, JAK inhibitors to JAK/STAT pathway, HDACIs to epigenetic aberrations, and AKT/mTOR inhibitor, may be promising therapeutic strategies in treating NKTCL. In the future, scientific research on NKTCL should be strengthened in China, focusing on EBV‐related pathogenesis, prognostic study in the next‐generation sequencing era, as well as genetic abnormalities in relapsed/refractory NKTCL. Meanwhile, multi‐center clinical trial should be carried out in Asia‐Pacific countries, to further obtain the randomized data of L‐ASP‐based regimens, to finally realize precision medicine and to make NKTCL a curable disease.